Hesperetin has demonstrated its ability to modulate inflammatory cytokine release, NF-κB acetylation, and SIRT 3/6 expression through the TLR/MyD88/NF-κB signaling pathways, suggesting its promise as a treatment option for averting diabetes and its associated complications. The gene discussed is MYD88; the disease is diabetes mellitus.